TISIDB

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted, extracellular space, extracellular matrix.
Domain	PF11598 Cartilage oligomeric matrix protein PF07645 Calcium-binding EGF domain PF02412 Thrombospondin type 3 repeat PF05735 Thrombospondin C-terminal region
Function	May play a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins such as the collagens and fibronectin. Can mediate the interaction of chondrocytes with the cartilage extracellular matrix through interaction with cell surface integrin receptors. Could play a role in the pathogenesis of osteoarthritis. Potent suppressor of apoptosis in both primary chondrocytes and transformed cells. Suppresses apoptosis by blocking the activation of caspase-3 and by inducing the IAP family of survival proteins (BIRC3, BIRC2, BIRC5 and XIAP). Essential for maintaining a vascular smooth muscle cells (VSMCs) contractile/differentiated phenotype under physiological and pathological stimuli. Maintains this phenotype of VSMCs by interacting with ITGA7 (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0003416 endochondral bone growth GO:0003417 growth plate cartilage development GO:0030198 extracellular matrix organization GO:0035265 organ growth GO:0043062 extracellular structure organization GO:0048705 skeletal system morphogenesis GO:0048736 appendage development GO:0051216 cartilage development GO:0060173 limb development GO:0060348 bone development GO:0060349 bone morphogenesis GO:0060350 endochondral bone morphogenesis GO:0060351 cartilage development involved in endochondral bone morphogenesis GO:0061448 connective tissue development GO:0098868 bone growth
Molecular Function	GO:0001948 glycoprotein binding GO:0002020 protease binding GO:0005201 extracellular matrix structural constituent GO:0005518 collagen binding GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0043394 proteoglycan binding GO:0043395 heparan sulfate proteoglycan binding GO:1901681 sulfur compound binding
Cellular Component	GO:0005578 proteinaceous extracellular matrix

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04145 Phagosome hsa04151 PI3K-Akt signaling pathway hsa04510 Focal adhesion hsa04512 ECM-receptor interaction
Reactome	R-HSA-3000178: ECM proteoglycans R-HSA-1474244: Extracellular matrix organization R-HSA-216083: Integrin cell surface interactions

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between COMP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of COMP in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of COMP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.841	0.0205
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.941	0.273
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.741	0.13
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.031	0.968
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.087	0.965
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.182	0.942
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.326	0.74
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.269	0.857
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.512	0.738
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.431	0.83
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.584	0.539
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.45	0.235

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of COMP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of COMP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of COMP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by COMP. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of COMP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of COMP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between COMP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	COMP
Name	cartilage oligomeric matrix protein
Aliases	THBS5; thrombospondin-5; PSACH; EDM1; EPD1; cartilage oligomeric matrix protein (pseudoachondroplasia, epiph ......
Chromosomal Location	19p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting COMP collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting COMP.

ID	Name	Drug Type	Targets	#Targets
DB01373	Calcium	Small Molecule	ALPP, AOC1, ATP2C1, BMP4, CACNA1C, CAST, COMP, CP, MGP, PCDH19, PD ......	19

Browse COMP